Menu
Search
|

Menu

Close
X

Arrowhead Pharmaceuticals Inc ARWR.OQ (NASDAQ Stock Exchange Global Select Market)

29.28 USD
-0.00 (-0.00%)
As of Sep 18
Previous Close 29.28
Open 29.67
Volume 766,618
3m Avg Volume 700,817
Today’s High 29.67
Today’s Low 28.47
52 Week High 36.75
52 Week Low 10.41
Shares Outstanding (mil) 94.81
Market Capitalization (mil) 2,718.32
Forward P/E 390.49
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
83
FY18
16
FY17
31
FY16
0
EPS (USD)
FY19
0.374
FY18
-0.654
FY17
-0.467
FY16
-1.338
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
390.49
33.85
Price to Sales (TTM)
vs sector
28.68
7.90
Price to Book (MRQ)
vs sector
13.49
4.38
Price to Cash Flow (TTM)
vs sector
189.76
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
5.45
12.69
Return on Equity (TTM)
vs sector
6.07
17.13

EXECUTIVE LEADERSHIP

Douglass Given
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Christopher Anzalone
President, Chief Executive Officer, Director, Since 2007
Salary: $643,012.00
Bonus: $975,000.00
Kenneth Myszkowski
Chief Financial Officer, Since 2010
Salary: $384,841.00
Bonus: $180,000.00
Bruce Given
Chief Operating Officer, Since 2011
Salary: $450,362.00
Bonus: $445,900.00
Patrick O'Brien
General Counsel, Since 2015
Salary: $406,196.00
Bonus: $184,500.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

225 S Lake Ave Ste 1050
PASADENA   CA   91101-4820

Phone: +1626.3043400

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

SPONSORED STORIES